These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17325431)

  • 21. A seven-gene CpG-island methylation panel predicts breast cancer progression.
    Li Y; Melnikov AA; Levenson V; Guerra E; Simeone P; Alberti S; Deng Y
    BMC Cancer; 2015 May; 15():417. PubMed ID: 25986046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
    Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
    BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.
    Zhang S; Wang Y; Gu Y; Zhu J; Ci C; Guo Z; Chen C; Wei Y; Lv W; Liu H; Zhang D; Zhang Y
    Mol Oncol; 2018 Jun; 12(7):1047-1060. PubMed ID: 29675884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
    Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
    Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.
    Yang R; Pfütze K; Zucknick M; Sutter C; Wappenschmidt B; Marme F; Qu B; Cuk K; Engel C; Schott S; Schneeweiss A; Brenner H; Claus R; Plass C; Bugert P; Hoth M; Sohn C; Schmutzler R; Bartram CR; Burwinkel B
    Int J Cancer; 2015 Apr; 136(8):1845-55. PubMed ID: 25213452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semiparametric estimation of time-dependent ROC curves for longitudinal marker data.
    Zheng Y; Heagerty PJ
    Biostatistics; 2004 Oct; 5(4):615-32. PubMed ID: 15475423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.
    Zhang L; Yan DL; Yang F; Wang DD; Chen X; Wu JZ; Tang JH; Xia WJ
    Oncotarget; 2017 Jul; 8(28):45496-45505. PubMed ID: 28525377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.
    Draht MXG; Goudkade D; Koch A; Grabsch HI; Weijenberg MP; van Engeland M; Melotte V; Smits KM
    Clin Epigenetics; 2018; 10():35. PubMed ID: 29564023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrantly methylated DNA as a biomarker in breast cancer.
    Kristiansen S; Jørgensen LM; Guldberg P; Sölétormos G
    Int J Biol Markers; 2013; 28(2):141-50. PubMed ID: 23564623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study.
    Shindo T; Shimizu T; Nojima M; Niinuma T; Maruyama R; Kitajima H; Kai M; Itoh N; Suzuki H; Masumori N
    Urology; 2018 Mar; 113():71-78. PubMed ID: 29196070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
    Papadopoulou E; Davilas E; Sotiriou V; Georgakopoulos E; Georgakopoulou S; Koliopanos A; Aggelakis F; Dardoufas K; Agnanti NJ; Karydas I; Nasioulas G
    Ann N Y Acad Sci; 2006 Sep; 1075():235-43. PubMed ID: 17108217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
    Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
    Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
    Tang Q; Cheng J; Cao X; Surowy H; Burwinkel B
    Clin Epigenetics; 2016; 8():115. PubMed ID: 27895805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human age estimation from blood using mRNA, DNA methylation, DNA rearrangement, and telomere length.
    Zubakov D; Liu F; Kokmeijer I; Choi Y; van Meurs JBJ; van IJcken WFJ; Uitterlinden AG; Hofman A; Broer L; van Duijn CM; Lewin J; Kayser M
    Forensic Sci Int Genet; 2016 Sep; 24():33-43. PubMed ID: 27288716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.
    Lu CY; Chen SY; Peng HL; Kan PY; Chang WC; Yen CJ
    Oncotarget; 2017 Jan; 8(4):6406-6418. PubMed ID: 28031532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of spatiotemporal changes for the classification of dynamic contrast-enhanced magnetic-resonance breast lesions.
    Milenković J; Hertl K; Košir A; Zibert J; Tasič JF
    Artif Intell Med; 2013 Jun; 58(2):101-14. PubMed ID: 23548472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Epigenetic Markers for Precision Medicine.
    Dumitrescu RG
    Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.